LIVIVO - Search results -

Search results

Result 1 - 10 of total 4213

Article ; Online: B-doped SnO

Kumar, Sanjeev / Bhawna / Yadav, Sanjeev Kumar / Gupta, Akanksha / Kumar, Ravinder / Ahmed, Jahangeer / Chaudhary, Monika / Suhas / Kumar, Vinod

Environmental science and pollution research international

2022 Volume 29, Issue 31, Page(s) 47448–47461

Abstract: Boron-doped ... ...

Abstract	Boron-doped SnO
Language	English
Publishing date	2022-02-19
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1178791-0
ISSN	1614-7499 ; 0944-1344
ISSN (online)	1614-7499
ISSN	0944-1344
DOI	10.1007/s11356-022-18946-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Bonn / Germany

Z 5915: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Hepatitis B

Mohan B Sannathimmappa / Vinod Nambiar / Rajeev Arvindakshan

Avicenna Journal of Medicine, Vol 9, Iss 02, Pp 43-

Knowledge and awareness among preclinical year medical students

2019 Volume 47

Abstract: Background and Objective: Hepatitis B is an occupational health hazard to health-care workers ... The complete knowledge of hepatitis B virus (HBV) transmission and prevention is indispensable ... for medical students. This study was conducted to assess the knowledge and awareness of hepatitis B among preclinical ...

Abstract	Background and Objective: Hepatitis B is an occupational health hazard to health-care workers. The complete knowledge of hepatitis B virus (HBV) transmission and prevention is indispensable for medical students. This study was conducted to assess the knowledge and awareness of hepatitis B among preclinical year medical students.Materials and Methods: This is a descriptive cross-sectional study. A predesigned self-administered questionnaire concerning hepatitis B knowledge and awareness was distributed to all the preclinical year medical students. The data were collected, tabulated, and analyzed by Microsoft Excel and Statistical Package for the Social Sciences (SPSS) software, version 22. The results were expressed in numbers and percentages.Results: Of 251 students, only 132 students voluntarily participated in the study. Majority of the students (84.8%) were aware of HBV infection. Many students knew that blood transfusion (81.1%) and use of contaminated needles and syringes (74.2%) are major modes of transmission. However, less than 30% of the students had knowledge about other modes of transmission. More than 50% of the students lacked in their knowledge about clinical features and complications of hepatitis B infection. Majority of students (72.7%) were aware of HBV vaccination. However, many students did not know their vaccination status, whereas only 23.5% of the students were fully immunized.Conclusion: This study revealed lack of complete knowledge regarding hepatitis B among preclinical year medical students. They are at high risk of acquiring HBV infection during their clinical practice, later in life. Hence, implementation of well-structured education program in the first year itself is needed to create complete awareness among medical students about hepatitis B.
Keywords	blood transfusion ; cirrhosis ; jaundice ; liver cancer ; vaccination ; Medicine ; R
Subject code	420 ; 028
Language	English
Publishing date	2019-04-01T00:00:00Z
Publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.

Agrawal, Vaibhav / Pourhassan, Hoda / Tsai, Ni-Chun / Ngo, Dat / Koller, Paul / Malki, Monzr M Al / Salhotra, Amandeep / Ali, Haris / Aribi, Ahmed / Sandhu, Karamjeet S / Arslan, Shukaib / Ball, Brian / Otoukesh, Salman / Amanam, Idoroenyi / Artz, Andrew / Singh, Dupinder / Becker, Pamela S / Stewart, Forrest M / Smith, Eileen P /

Curtin, Peter / Stein, Anthony S / Marcucci, Guido / Forman, Stephen J / Nakamura, Ryotaro / Pullarkat, Vinod / Aldoss, Ibrahim

Transplantation and cellular therapy

2023 Volume 29, Issue 5, Page(s) 314–320

Abstract: Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication that can be observed after allogeneic hematopoietic cell transplantation (HCT). Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody-drug conjugate that has ... ...

Abstract	Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication that can be observed after allogeneic hematopoietic cell transplantation (HCT). Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody-drug conjugate that has demonstrated high efficacy in relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) but is associated with an increased risk of SOS in HCT recipients. Here we aimed to examine the incidence and outcomes of SOS in 47 adult patients with R/R ALL who received inotuzumab therapy and subsequently underwent HCT at our institution. All patients received prophylactic therapy with ursodiol, and continuous low-dose heparin also was administered to patients receiving myeloablative conditioning (MAC). SOS occurred in 12 patients (26%) post-HCT, at a median onset of 11 days (range, 3 to 41 days). SOS was graded as very severe in 50% (n = 6), severe in 25% (n = 3), and mild in 25% (n = 3). All patients diagnosed with SOS received treatment with defibrotide for a median of 21 days (range, 3 to 34 days), with resolution of SOS occurring in 8 patients (67%). Mortality from SOS was 33% (n = 4) and occurred at a median of 10 days from diagnosis (range, 3 to 31 days) in patients graded as very severe (n = 3) or severe (n = 1). There were no significant differences between patients who developed SOS and those who did not develop SOS in the median time from the last dose of inotuzumab to transplantation (46 days versus 53 days; P = .37), use of an MAC regimen (42% versus 49%; P = .75), number of lines of therapy prior to inotuzumab (P = .79), median number of administered cycles of inotuzumab (2 versus 2; P = .14), or receipt of inotuzumab as the last therapy prior to HCT (67% versus 66%; P = 1.0). Sirolimus-based graft-versus-host disease (GVHD) prophylaxis was used more frequently in the SOS group (75% versus 29%; P < .01), but there was no between-group difference in the peak sirolimus level (P = .81) or the median time to peak sirolimus level (7 days versus 3.5 days; P = .39). In univariable analysis, only the use of sirolimus-based GVHD prophylaxis was significantly associated with an increased risk of SOS (hazard ratio [HR], 7.50; 95% confidence interval [CI], 1.7 to 33.6; P < .01). In the SOS group, the 100-day mortality rate was 33% (n = 4), and median overall survival (OS) post-HCT was 4.3 months (range, 0.2 to 57.2 months). In the group without SOS, the 100-day mortality rate was 14% (n = 5) and the median OS post-HCT was 10.7 months (range, .52 to 39.6 months). In this study cohort, SOS was prevalent in HCT recipients who had been treated with inotuzumab prior to transplantation, and sirolimus-based GVHD prophylaxis was a risk factor for SOS in inotuzumab recipients.
MeSH term(s)	Humans ; Adult ; Hepatic Veno-Occlusive Disease/drug therapy ; Hepatic Veno-Occlusive Disease/etiology ; Inotuzumab Ozogamicin/adverse effects ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/chemically induced ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/complications ; Sirolimus ; Burkitt Lymphoma/chemically induced ; Burkitt Lymphoma/complications ; Graft vs Host Disease/prevention & control
Chemical Substances	Inotuzumab Ozogamicin (P93RUU11P7) ; Sirolimus (W36ZG6FT64)
Language	English
Publishing date	2023-01-19
Publishing country	United States
Document type	Journal Article
ZDB-ID	3062231-1
ISSN	2666-6367
ISSN (online)	2666-6367
DOI	10.1016/j.jtct.2023.01.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5082: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment.

Pourhassan, Hoda / Agrawal, Vaibhav / Pullarkat, Vinod / Aldoss, Ibrahim

Frontiers in oncology

2023 Volume 13, Page(s) 1237031

Abstract: ... negative and Ph-positive B-ALL, and this has extended to older adults with ALL who have historically had ... the current data describing the early use of blinatumomab in newly diagnosed adults with B-cell ALL and future ...

Abstract	Blinatumomab is a bispecific T cell engager that has shown efficacy in relapsed/refractory Philadelphia chromosome (Ph)-positive and Ph-negative acute lymphoblastic leukemia (ALL). Considering its favorable safety and activity in advanced ALL, blinatumomab as a targeted immunotherapy is fast gaining a frontline position in the ALL treatment paradigm. There have been multiple completed and ongoing studies showing significant promise with improved response rates and survival outcomes and decreased treatment toxicity and need for multi-agent chemotherapy regimens. The early use of blinatumomab has established success in Ph-negative and Ph-positive B-ALL, and this has extended to older adults with ALL who have historically had substantially inferior outcomes compared to their pediatric and young adult counterparts. Herein we will review the current data describing the early use of blinatumomab in newly diagnosed adults with B-cell ALL and future directions.
Language	English
Publishing date	2023-08-17
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2023.1237031
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Maternal vitamin B

Tanwar, Vinay Singh / Ghosh, Sourav / Sati, Satish / Ghose, Subhoshree / Kaur, Lovejeet / Kumar, Kalle Anand / Shamsudheen, K V / Patowary, Ashok / Singh, Meghna / Jyothi, V / Kommineni, Pujitha / Sivasubbu, Sridhar / Scaria, Vinod / Raghunath, Manchala / Mishra, Rakesh / Chandak, Giriraj Ratan / Sengupta, Shantanu

Molecular and cellular biochemistry

2020 Volume 468, Issue 1-2, Page(s) 83–96

Abstract: Vitamin B ...

Abstract	Vitamin B
MeSH term(s)	Animals ; Animals, Newborn ; CpG Islands/genetics ; DNA Methylation ; Fatty Acids/genetics ; Fatty Acids/metabolism ; Female ; High-Throughput Nucleotide Sequencing ; Immunoprecipitation ; Insulin Resistance/genetics ; Liver/metabolism ; Male ; Mitochondria/genetics ; Mitochondria/metabolism ; Obesity/metabolism ; Phenotype ; Pregnancy ; Prenatal Exposure Delayed Effects/genetics ; Prenatal Exposure Delayed Effects/metabolism ; Rats ; Rats, Wistar ; Signal Transduction/genetics ; Vitamin B 12/metabolism ; Vitamin B 12 Deficiency
Chemical Substances	Fatty Acids ; Vitamin B 12 (P6YC3EG204)
Language	English
Publishing date	2020-03-18
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	184833-1
ISSN	1573-4919 ; 0300-8177
ISSN (online)	1573-4919
ISSN	0300-8177
DOI	10.1007/s11010-020-03713-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 892: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome.

Viswanathan, Aswathi / Kundal, Kavita / Sengupta, Avik / Kumar, Ambuj / Kumar, Keerthana Vinod / Holmes, Antony B / Kumar, Rahul

Briefings in functional genomics

2022 Volume 22, Issue 1, Page(s) 42–48

Abstract: Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma with poor ...

Abstract	Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma with poor response to R-CHOP therapy due to remarkable heterogeneity. Based on gene expression, DLBCL cases were divided into two subtypes, i.e. ABC and GCB, where ABC subtype is associated with poor outcomes. Due to its association with clinical outcome, this classification, also known as cell-of-origin (COO), is an efficient way to predict the response to R-CHOP therapy. Previous COO classification methods have some shortcomings, e.g. limited number of samples in the training dataset. These shortcomings challenge the robustness of methods and make it difficult to implicate these methods at clinical level. To overcome the shortcomings of previous methods, we developed a deep learning-based classifier model on a cohort of 381 DLBCL patients using expression data of 20 genes. We implemented multilayer perceptron (MLP) to train deep learning-based classifier, named MLP-COO. MLP-COO achieved accuracy of 99.70% and 94.70% on training and testing datasets, respectively, with 10-fold cross-validation. We also assessed its performance on an independent dataset of 294 DLBCL patients. On independent dataset, we achieved an accuracy of 95.90% with MCC of 0.917. To show its broader applicability, we used this classifier to predict the clinical outcome using survival data from two large cohorts of DLBCL patients. In survival analysis, MLP-COO recapitulates the survival probabilities of DLBCL patients based on their COO in both cohorts. We anticipate that MLP-COO model developed in this study will benefit in the accurate COO prediction of DLBCL patients and their clinical outcomes.
MeSH term(s)	Humans ; Deep Learning ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Rituximab/therapeutic use ; Rituximab/genetics ; Genetic Techniques ; Cyclophosphamide/therapeutic use
Chemical Substances	Rituximab (4F4X42SYQ6) ; Cyclophosphamide (8N3DW7272P)
Language	English
Publishing date	2022-12-03
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2540916-5
ISSN	2041-2657 ; 2041-2649 ; 2041-2647
ISSN (online)	2041-2657
ISSN	2041-2649 ; 2041-2647
DOI	10.1093/bfgp/elac038
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6076: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Sustained Liver HBsAg Loss and Clonal T- and B-Cell Expansion upon Therapeutic DNA Vaccination Require Low HBsAg Levels.

Vaccines

2023 Volume 11, Issue 12

Abstract: Background: Suppression of HBV DNA, inhibition of HBV surface (HBsAg) production and therapeutic vaccination to reverse HBV-specific T-cell exhaustion in chronic HBV patients are likely required to achieve a functional cure. In the AAV-HBV mouse model, ... ...

Abstract	Background: Suppression of HBV DNA, inhibition of HBV surface (HBsAg) production and therapeutic vaccination to reverse HBV-specific T-cell exhaustion in chronic HBV patients are likely required to achieve a functional cure. In the AAV-HBV mouse model, therapeutic vaccination can be effective in clearing HBV when HBsAg levels are low. Using a single-cell approach, we investigated the liver immune environment with different levels of HBsAg and sustained HBsAg loss through treatment with a GalNAc-HBV-siRNA followed by therapeutic vaccination. Methods: AAV-HBV-transduced C57BL/6 mice were treated with GalNAc-HBV-siRNA to lower HBsAg levels and then vaccinated using a DNA vaccine. We used single-cell RNA and V(D)J sequencing to understand liver immune microenvironment changes. Results: GalNAc-HBV-siRNA, followed by therapeutic vaccination, achieved sustained HBsAg loss in all mice. This was accompanied by CD4 follicular helper T-cell induction, polyclonal activation of CD8 T cells and clonal expansion of plasma cells that were responsible for antibody production. Conclusions: This study provides novel insights into liver immune changes at the single-cell level, highlighting the correlation between induced reduction of HBsAg levels and clonal expansion of CD4, CD8 T cells and plasma cells in the liver upon HBV siRNA and subsequent therapeutic vaccination.
Language	English
Publishing date	2023-12-06
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines11121825
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint.

Floudas, Achilleas / Neto, Nuno / Marzaioli, Viviana / Murray, Kieran / Moran, Barry / Monaghan, Michael G / Low, Candice / Mullan, Ronan H / Rao, Navin / Krishna, Vinod / Nagpal, Sunil / Veale, Douglas J / Fearon, Ursula

JCI insight

2020 Volume 5, Issue 21

Abstract: ... of B cells in the inflamed joint remains elusive. Extensive flow cytometric characterization and SPICE ... of switched and double-negative memory programmed death-1 receptor-expressing (PD-1-expressing) B ... cells at the site of inflammation. Accumulation of memory B cells was mediated by CXCR3, evident by the observed ...

Abstract	While autoantibodies are used in the diagnosis of rheumatoid arthritis (RA), the function of B cells in the inflamed joint remains elusive. Extensive flow cytometric characterization and SPICE algorithm analyses of single-cell synovial tissue from patients with RA revealed the accumulation of switched and double-negative memory programmed death-1 receptor-expressing (PD-1-expressing) B cells at the site of inflammation. Accumulation of memory B cells was mediated by CXCR3, evident by the observed increase in CXCR3-expressing synovial B cells compared with the periphery, differential regulation by key synovial cytokines, and restricted B cell invasion demonstrated in response to CXCR3 blockade. Notably, under 3% O2 hypoxic conditions that mimic the joint microenvironment, RA B cells maintained marked expression of MMP-9, TNF, and IL-6, with PD-1+ B cells demonstrating higher expression of CXCR3, CD80, CD86, IL-1β, and GM-CSF than their PD-1- counterparts. Finally, following functional analysis and flow cell sorting of RA PD-1+ versus PD-1- B cells, we demonstrate, using RNA-Seq and emerging fluorescence lifetime imaging microscopy of cellular NAD, a significant shift in metabolism of RA PD-1+ B cells toward glycolysis, associated with an increased transcriptional signature of key cytokines and chemokines that are strongly implicated in RA pathogenesis. Our data support the targeting of pathogenic PD-1+ B cells in RA as a focused, novel therapeutic option.
MeSH term(s)	Arthritis, Rheumatoid/immunology ; Arthritis, Rheumatoid/metabolism ; Arthritis, Rheumatoid/pathology ; B-Lymphocytes/immunology ; B-Lymphocytes/metabolism ; Case-Control Studies ; Glycolysis ; Humans ; Hypoxia/physiopathology ; Inflammation/immunology ; Inflammation/metabolism ; Inflammation/pathology ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism ; Receptors, CXCR3 ; Synovial Membrane/immunology ; Synovial Membrane/metabolism
Chemical Substances	CXCR3 protein, human ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; Receptors, CXCR3
Language	English
Publishing date	2020-11-05
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2379-3708
ISSN (online)	2379-3708
DOI	10.1172/jci.insight.139032
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.

Agrawal, Vaibhav / Murphy, Lindsey / Pourhassan, Hoda / Pullarkat, Vinod / Aldoss, Ibrahim

European journal of haematology

2023 Volume 112, Issue 2, Page(s) 236–247

Abstract: ... in the treatment of various hematologic malignancies including relapsed or refractory (R/R) B-cell ... acute lymphoblastic leukemia (B-ALL). Currently, there are two FDA-approved CD19-directed CAR-T cell products for the treatment ... of adults with R/R B-ALL. Despite high remission rates following CD19 CAR-T cell therapy in R/R B ...

Abstract	Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated unprecedented success in the treatment of various hematologic malignancies including relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Currently, there are two FDA-approved CD19-directed CAR-T cell products for the treatment of adults with R/R B-ALL. Despite high remission rates following CD19 CAR-T cell therapy in R/R B-ALL, remission durability remains limited in most adult patients, with relapse observed frequently in the absence of additional consolidation therapy. Furthermore, the burden of CAR-T cell toxicity remains significant in adults with R/R B-ALL and further limits the wide utilization of this effective therapy. In this review, we discuss patient and disease factors that are linked to CAR-T cell therapy outcomes in R/R B-ALL and strategies to optimize durability of response to reduce relapse and mitigate toxicity in the adult population. We additionally discuss future approaches being explored to maximize the benefit of CAR-T in adults with B-ALL.
MeSH term(s)	Adult ; Humans ; Receptors, Chimeric Antigen/genetics ; Immunotherapy, Adoptive/adverse effects ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Burkitt Lymphoma ; Antigens, CD19 ; Recurrence ; Cell- and Tissue-Based Therapy
Chemical Substances	Receptors, Chimeric Antigen ; Antigens, CD19
Language	English
Publishing date	2023-09-29
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	392482-8
ISSN	1600-0609 ; 0902-4441
ISSN (online)	1600-0609
ISSN	0902-4441
DOI	10.1111/ejh.14109
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 323: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Hepatitis B: Knowledge and awareness among preclinical year medical students.

Sannathimmappa, Mohan B / Nambiar, Vinod / Arvindakshan, Rajeev

Avicenna journal of medicine

2019 Volume 9, Issue 2, Page(s) 43–47

Abstract: Background and objective: Hepatitis B is an occupational health hazard to health-care workers ... The complete knowledge of hepatitis B virus (HBV) transmission and prevention is indispensable ... for medical students. This study was conducted to assess the knowledge and awareness of hepatitis B among preclinical ...

Abstract	Background and objective: Hepatitis B is an occupational health hazard to health-care workers. The complete knowledge of hepatitis B virus (HBV) transmission and prevention is indispensable for medical students. This study was conducted to assess the knowledge and awareness of hepatitis B among preclinical year medical students. Materials and methods: This is a descriptive cross-sectional study. A predesigned self-administered questionnaire concerning hepatitis B knowledge and awareness was distributed to all the preclinical year medical students. The data were collected, tabulated, and analyzed by Microsoft Excel and Statistical Package for the Social Sciences (SPSS) software, version 22. The results were expressed in numbers and percentages. Results: Of 251 students, only 132 students voluntarily participated in the study. Majority of the students (84.8%) were aware of HBV infection. Many students knew that blood transfusion (81.1%) and use of contaminated needles and syringes (74.2%) are major modes of transmission. However, less than 30% of the students had knowledge about other modes of transmission. More than 50% of the students lacked in their knowledge about clinical features and complications of hepatitis B infection. Majority of students (72.7%) were aware of HBV vaccination. However, many students did not know their vaccination status, whereas only 23.5% of the students were fully immunized. Conclusion: This study revealed lack of complete knowledge regarding hepatitis B among preclinical year medical students. They are at high risk of acquiring HBV infection during their clinical practice, later in life. Hence, implementation of well-structured education program in the first year itself is needed to create complete awareness among medical students about hepatitis B.
Language	English
Publishing date	2019-04-29
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2664414-9
ISSN	2249-4464 ; 2231-0770
ISSN (online)	2249-4464
ISSN	2231-0770
DOI	10.4103/ajm.AJM_164_18
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito